An open label study to evaluate the safety and effect on sustained virological response of Pegasys [peginterferon-alfa-2a] plus ribavirin in patients with hemophilia A and chronic hepatitis C

Trial Profile

An open label study to evaluate the safety and effect on sustained virological response of Pegasys [peginterferon-alfa-2a] plus ribavirin in patients with hemophilia A and chronic hepatitis C

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 May 2013

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 26 Mar 2008 The expected completion date for this trial is now 1 Jul 2006.
    • 30 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top